🇺🇸 FDA

Intelligence Platform

Patents

Browse 650 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9890210

Antagonist antibodies directed against calcitonin gene-related peptide

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9884908

Methods for treating headache using antagonist antibodies directed against calcitonin gene

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9884907

Methods for treating headache using antagonist antibodies directed against calcitonin gene

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9809623

α4β7 peptide monomer and dimer antagonists

Protagonist Therapeutics, Inc. · Granted Tue Nov 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9801938

Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists

FREISTAAT BAYERN REPRESENTED BY JULIUS-MAXIMILLIANS-UNIVERSITÄT WÜRZBURG · Granted Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9790220

Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonis

Takeda Pharmaceutical Company Limited · Granted Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9771350

Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist

Theravance Respiratory Company, LLC · Granted Tue Sep 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9757383

Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist acti

Almirall, S.A. · Granted Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9751878

Tetrahydronaphthyridine somatostatin receptor 5 antagonists

Takeda Pharmaceutical Company Limited · Granted Tue Sep 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9717752

Uses of antagonists of hyaluronan signaling

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9714270

a4B7 integrin thioether peptide antagonists

Protagonist Therapeutics, Inc. · Granted Tue Jul 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9695195

5-HT3 receptor antagonists

Takeda Pharmaceutical Company Limited · Granted Tue Jul 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9682957

Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonis

Theravance Respiratory Company, LLC · Granted Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9670229

5-HT3 receptor antagonists

Takeda Pharmaceutical Company Limited · Granted Tue Jun 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9669069

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9663509

8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Theravance Biopharma R&D IP, LLC · Granted Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9643961

Cyclohexylamine derivatives having β2 adrenergic antagonist and M3 muscarinic antagonist a

Almirall, S.A. · Granted Tue May 09 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 04 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9636400

VEGF specific fusion protein antagonist formulations

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9637535

IL-33 antagonists and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9631001

Peptide antagonists of the vasopressin-2 receptor

Universität Regensburg · Granted Tue Apr 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9624182

Compounds as lysophosphatidic acid receptor antagonists

AMIRA PHARMACEUTICALS, INC. · Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9605000

Spiro azetidine isoxazole derivatives and their use as SSTR antagonists

Takeda Pharmaceutical Company Limited · Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9580489

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9579316

Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both muscar

Almirall, S.A. · Granted Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted